by Nisha Cooch, PhD | Sep 10, 2019 | Neurologists Resource Page Two, Neurologists Resource Pages, Nursing Resource Page Two, Nursing Resource Pages
As Zolgensma was recently approved by the FDA – in May 2019 – there has been little caregiver education on the therapy and how best to monitor SMA patients undergoing the treatment. Specifically, caregivers should be provided information on how best to...
by Nisha Cooch, PhD | Sep 10, 2019 | Neurologists Resource Page One, Neurologists Resource Pages, Nursing Resource Page One, Nursing Resource Pages, Pediatricians Resource Page One, Pediatricians Resources, Radiology Resource Page One, Radiology Resources
Zolgensma, or onasemnogene abeparvovec, is an adeno-associated virus vector-based gene therapy that was approved by the FDA in May 2019. Given the newness of this therapy, it is important that healthcare providers are educated on specific information regarding the...
by Nisha Cooch, PhD | Jan 28, 2019 | Genetic Counselor Resource Page One, Genetic Counselor Resource Pages, Neurologists Resource Page One, Neurologists Resource Pages, Nursing Resource Page One, Nursing Resource Pages, Nutritionist Resource Page One, Nutritionist Resource Pages, Orthopedics Resource Page One, Orthopedics Resource Pages, Pediatricians Resource Page One, Pediatricians Resources, Physical Therapists Resource Page One, Physical Therapists Resource Pages, Pulmonologist Resource Page One, Pulmonologist Resource Pages, Radiology Resource Page One, Radiology Resources, Social Worker Resource Page One, Social Worker Resource Pages, Urologist Resource Page One, Urologist Resources
At the end of 2016, the U.S. Food and Drug Administration (FDA) approved nusinersen for the treatment of spinal muscular atrophy (SMA).1 Because of the high threshold for FDA approval, an abundance of data on nusinersen and its physiological effects on SMA patients...
by Michael Nace | Jan 15, 2019 | Neurologists Resource Page Two, Neurologists Resource Pages, Nursing Resource Page Two, Nursing Resource Pages, Radiology Resource Page One, Radiology Resources
Nusinersen is the first treatment available for children with spinal muscular atrophy (SMA). Before its approval in 2016, the U.S. Food and Drug Administration had not approved the use of any drug for SMA treatment.1 While the introduction of this new drug marks...
by Michael Nace | Jan 7, 2019 | Nursing Resource Page Two, Nursing Resource Pages, Nutritionist Resource Page Two, Nutritionist Resource Pages, Orthopedics Resource Page Two, Orthopedics Resource Pages, Pediatricians Resource Page Two, Pediatricians Resources
Those with spinal muscular atrophy (SMA) often suffer from sleep disorders, but the specific reasons for sleep disturbances vary. For instance, some studies on SMA report sleep disturbances resulting from breathing disorders like sleep apneas, whereas others report...
by Michael Nace | Jan 7, 2019 | Neurologists Resource Page Two, Neurologists Resource Pages, Nursing Resource Page One, Nursing Resource Pages, Orthopedics Resource Page One, Orthopedics Resource Pages, Pediatricians Resource Page One, Pediatricians Resources, Pulmonologist Resource Page One, Pulmonologist Resource Pages, Social Worker Resource Page One, Social Worker Resource Pages
A tool that is commonly used to evaluate motor function in spinal muscular atrophy (SMA) patients is the Hammersmith Functional Motor Scale (HFMSE).1 Given the extensive use of this tool, particularly for clinical trial research that aims to identify and develop...
